Book Description

The updated visual atlas of family medicine—enhanced by more than 2,000 illustrations A Doody's Core Title for 2021! "The Color Atlas and Synopsis of Family Medicine, Third Edition, will be an invaluable addition to busy physicians’ clinical libraries. Its wide-ranging topics covering the gamut of family medicine are thoroughly covered and efficiently organized for point-of-care use. This, as well as its useful and exceptional photographs, will make it a resource the clinician will reach for again and again during evaluation of unfamiliar conditions. Residents and students will find it particularly useful as they systematically broaden their experiences and fund of knowledge—well done! " —Family Medicine The Color Atlas and Synopsis of Family Medicine simplifies and supports visual diagnosis like no other guide. The text is bolstered by more than 2,000 illustrations, consisting of state-of-the-art photos and drawings, most in full color. Page after page, the book’s precise clinical images are integrated with evidence-based diagnostic pearls presented in bulleted text—ideal for time-pressed physicians. Sections highlight specific diseases and disorders, organized by anatomic and physiologic systems, with each chapter opening with a patient story to connect the photographs with real-life clinical scenarios. Every condition features a consistent format that includes the patient story, Epidemiology, Etiology and Pathophysiology, Diagnosis, Differential Diagnosis, and Management to aid the reader in navigating to the right section with ease and efficiency. NEW TO THIS EDITION: New chapters on Mental Health, the Opioid Crisis, Dementia, Sports-related Head Injury, and LGBT health issues New chapter on Zika, Ebola and other emerging infections expand the insights in the Global Health chapter New Foundations of Dermatology section contains a dermoscopy chapter, plus chapters on dermatology terminology, topical and intralesional steroids, and biopsy principles and techniques Management section is now divided into first- and second-line therapies